Checkpoint Therapeutics Overview
- Founded
-
2014

- Status
-
Public
- Employees
-
18

- Stock Symbol
-
CKPT

- Investments
-
1
- Share Price
-
$3.82
- (As of Monday Closing)
Checkpoint Therapeutics General Information
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Contact Information
- 95 Sawyer Road
- Suite 110
- Waltham, MA 02453
- United States
Checkpoint Therapeutics Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$3.82 | $3.72 | $3.45 - $19.00 | $42.5M | 11.4M | 211K | -$8.70 |
Checkpoint Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 65,310 | 200,331 | 137,862 | 79,166 |
Revenue | 134 | 268 | 1,069 | 1,708 |
EBITDA | (71,459) | (56,723) | (23,201) | (24,850) |
Net Income | (71,358) | (56,670) | (23,081) | (24,714) |
Total Assets | 21,620 | 55,728 | 42,596 | 26,966 |
Total Debt | 0 | 0 | 0 | 0 |
Checkpoint Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Checkpoint Therapeutics Comparisons
Industry
Financing
Details
Checkpoint Therapeutics Competitors (26)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Amgen | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
000000000 00000000 | Venture Capital-Backed | Hennigsdorf, Germany | 00 | 000.00 | 0000000000 0 | 000.00 |
000000 | Formerly VC-backed | Wilmington, DE | 0000 | 00000000000 | ||
000000 00000000000 | Corporation | New York, NY | 00 | 00000 | 000000000 | 00000 |
000000 00000000000 | Venture Capital-Backed | New York, NY | 000.00 | 00000000000 | 000.00 |
Checkpoint Therapeutics Patents
Checkpoint Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2017290709-A1 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | |
CA-3027204-A1 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | |
EP-3478723-A2 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | |
EP-3478723-A4 | Pd-l1-specific antibodies and methods of using the same | Pending | 29-Jun-2016 | 00000000000 | 0 |
JP-2022120008-A | Pd-l1-specific antibody and method of using the same | Pending | 29-Jun-2016 | C07K16/2827 |
Checkpoint Therapeutics Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
James Oliviero III | Chief Executive Officer & Board Member | ||
Garrett Gray | Chief Financial Officer |
Checkpoint Therapeutics Board Members (3)
Name | Representing | Role | Since |
---|---|---|---|
00000 00000000 000 | Checkpoint Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
0000000 00000 00 | Self | Chairman & Board Member | 000 0000 |
0000 0000000000 | Self | Board Member | 000 0000 |
Checkpoint Therapeutics Signals
Checkpoint Therapeutics Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000000 (00 | 000000000 | Buildings and Property |
Checkpoint Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2021
47.19 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile

Pharmaceuticals
Industry
00 of 947
Rank
Percentile

Pharmaceuticals
Subindustry
00 of 452
Rank
Percentile
